This inventor holds 4 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignees: University of California, Other. Active years: 2015-2025.
Company Filing History:
3 out of 15,964 
1 out of 834,307 Years Active: 2015-2025
Title: Shantanu Kumar: Innovator in Tumor-Selective Gene Therapy
Introduction
Shantanu Kumar is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of gene therapy, particularly in developing tumor-selective expression systems. With a total of 4 patents, his work has the potential to advance cancer treatment methodologies.
Latest Patents
Kumar's latest patents focus on tumor-selective E1a and E1b mutants. These patents provide modified E1a regulatory sequences, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Additionally, modified E1a sequences that selectively express particular isoforms are included. An E1b-19K clone insertion site is also provided. These modified sequences can be utilized individually or in combination to achieve tumor-selective expression of proteins.
Career Highlights
Throughout his career, Shantanu Kumar has worked with esteemed institutions, including the University of California. His innovative approaches have garnered attention in the scientific community, contributing to advancements in cancer research.
Collaborations
Kumar has collaborated with notable professionals in his field, including Tony R Reid and Farah Hedjran. These partnerships have facilitated the exchange of ideas and fostered innovation in tumor-selective therapies.
Conclusion
Shantanu Kumar's work in tumor-selective gene therapy exemplifies the impact of innovative thinking in medical science. His patents and collaborations continue to pave the way for advancements in cancer treatment.